PURPOSE To increase awareness, outline strategies, and offer guidance on the
recommended management of immune-related adverse events (irAEs) in patients treated …

Purpose To increase awareness, outline strategies, and offer guidance on the
recommended management of immune-related adverse events in patients treated with …

Immune-related adverse events (irAEs) associated with immune checkpoint inhibitor (ICI)
therapy may vary substantially in their clinical presentation, including natural history …

Immune checkpoint inhibitors (ICIS) such as inhibitors of CTLA-4, PD-1, and PD-L1, given as
monotherapy or combination therapy have emerged as effective treatment options for …

Successful targeting and inhibition of the cytotoxic T-lymphocyte-associated antigen 4 and
programmed cell death-1 protein/programmed cell death ligand 1 immune checkpoint …

Immune checkpoint inhibitors (ICIs) are the standard of care for the treatment of several
cancers. While these immunotherapies have improved patient outcomes in many clinical …

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer, improving
outcomes in patients with advanced malignancies. The use of ICIs in clinical practice, and …

Importance Toxic effects of conventional chemotherapy and molecularly targeted cancer
therapies are generally well defined and occur at predictable points. By contrast, owing to …

Background A number of studies have reported an association between the occurrence of
immune-related adverse events (irAEs) and clinical efficacy in patients undergoing treatment …

Cancer immunotherapy has transformed the treatment of cancer. However, increasing use of
immune-based therapies, including the widely used class of agents known as immune …